和黄医药近日宣布,已正式启动其创新药物HMPL-A580的全球临床试验。该药物是一款针对PI3K/PI3K-EGFR双靶点的抗体-药物偶联物候选药物,此次试验旨在评估其在实体瘤患者中的安全性和有效性。
这项全球性研究的开展,标志着和黄医药在肿瘤治疗领域的研发管线取得了重要进展,也为晚期实体瘤患者带来了新的潜在治疗选择。
和黄医药近日宣布,已正式启动其创新药物HMPL-A580的全球临床试验。该药物是一款针对PI3K/PI3K-EGFR双靶点的抗体-药物偶联物候选药物,此次试验旨在评估其在实体瘤患者中的安全性和有效性。
这项全球性研究的开展,标志着和黄医药在肿瘤治疗领域的研发管线取得了重要进展,也为晚期实体瘤患者带来了新的潜在治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.